KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks
NASDAQ:CNAT
Delisted

Conatus Pharmaceuticals Inc. Stock Price (Quote)

$0.255
+0 (+0%)
At Close: May 27, 2022

Range Low Price High Price Comment
30 days $0.255 $0.255 Friday, 27th May 2022 CNAT stock ended at $0.255. During the day the stock fluctuated 0% from a day low at $0.255 to a day high of $0.255.
90 days $0.238 $0.275
52 weeks $0.203 $1.23

Historical Conatus Pharmaceuticals Inc. prices

Date Open High Low Close Volume
Feb 29, 2016 $1.88 $1.88 $1.75 $1.78 132 600
Feb 26, 2016 $1.78 $1.94 $1.78 $1.88 81 500
Feb 25, 2016 $1.85 $1.85 $1.77 $1.78 56 100
Feb 24, 2016 $1.85 $1.86 $1.75 $1.86 76 300
Feb 23, 2016 $1.93 $1.94 $1.83 $1.86 119 100
Feb 22, 2016 $1.91 $1.94 $1.87 $1.91 63 300
Feb 19, 2016 $1.88 $1.91 $1.85 $1.91 38 000
Feb 18, 2016 $1.90 $1.91 $1.84 $1.89 61 300
Feb 17, 2016 $1.76 $1.91 $1.76 $1.88 239 700
Feb 16, 2016 $1.77 $1.85 $1.73 $1.73 140 600
Feb 12, 2016 $1.65 $1.77 $1.61 $1.73 229 600
Feb 11, 2016 $1.60 $1.66 $1.55 $1.65 139 700
Feb 10, 2016 $1.66 $1.72 $1.60 $1.65 142 300
Feb 09, 2016 $1.60 $1.79 $1.60 $1.67 303 400
Feb 08, 2016 $1.76 $1.84 $1.64 $1.69 494 100
Feb 05, 2016 $1.84 $1.85 $1.76 $1.84 208 900
Feb 04, 2016 $1.90 $1.93 $1.80 $1.85 581 200
Feb 03, 2016 $1.98 $2.08 $1.80 $1.96 6 388 500
Feb 02, 2016 $1.60 $1.69 $1.60 $1.60 152 300
Feb 01, 2016 $1.74 $1.74 $1.60 $1.64 118 300
Jan 29, 2016 $1.60 $1.74 $1.60 $1.74 118 600
Jan 28, 2016 $1.80 $1.80 $1.56 $1.60 175 400
Jan 27, 2016 $1.80 $1.86 $1.73 $1.73 97 700
Jan 26, 2016 $1.68 $1.82 $1.66 $1.82 151 600
Jan 25, 2016 $1.74 $1.90 $1.61 $1.65 235 400
Click to get the best stock tips daily for free!

About Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals. Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase II clinical trials for the treatment of liver cirrhosis, acute-on-chronic liver failure, post-orthotopic liver transplant as a result of hepatitis C virus infection with sust... CNAT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT